Key result
The Medly mobile phone-based telemonitoring program is the subject of a proposed randomized controlled trial protocol for heart failure patients, with no clinical results reported in this letter.
Why the study?
Telemonitoring reduces mortality and readmissions in heart failure, but its impact in patients recently discharged from hospital remains unknown.
Does Medly mobile phone-based telemonitoring improve self-care and quality of life in heart failure patients recently discharged after acute decompensation?
Does Medly mobile phone-based telemonitoring improve self-care and quality of life in heart failure patients recently discharged after acute decompensation?
This trial protocol describes a study to determine if a mobile phone-based telemonitoring program improves self-care and quality of life in patients recently discharged after acute heart failure decompensation.
Tests Medly TM in recently discharged HF patients; RCT extends evidence to the highest-risk transition period.
BACKGROUND: Patients with heart failure (HF) are at the highest risk for hospital readmissions during the first few weeks after discharge when patients are transitioning from hospital to home. Telemonitoring (TM) for HF management has been found to reduce mortality risk and hospital readmissions if implemented appropriately; however, the impact of TM targeted for patients recently discharged from hospital, for whom TM might have the biggest benefit, is still unknown. Medly, a mobile phone-based TM system that is currently being used as a standard of care for HF at a large Canadian hospital, may be an effective tool for the management of HF in patients recently discharged from hospital. OBJECTIVE: The objective of the Medly-After an Incidence of acute Decompensation (Medly-AID) trial is to determine the effect of Medly on the self-care and quality of life of patients with HF who have been recently discharged from hospital after an HF-related decompensation. METHODS: A multisite multimethod randomized controlled trial (RCT) will be conducted at 2 academic hospitals and at least one community hospital to evaluate the impact of Medly-enabled HF management on the outcomes of patients with HF who had been hospitalized for HF-related decompensation and discharged during the 2 weeks before recruitment. The trial will include 144 participants with HF (74 in each control and intervention groups). Control patients will receive standard of care, whereas patients in the intervention group will receive standard of care and Medly. Specifically, patients in the intervention group will record daily weight, blood pressure, and heart rate and answer symptom-related questions via the Medly app. Medly will generate automated patient self-care messages such as to adjust diuretic medications, based on the rules-based algorithm personalized to the individual patient, and send real-time alerts to their health care providers as necessary. All patients will be followed for 3 months. Primary outcome measures are self-care and quality of life as measured through the validated questionnaires Self-Care of Heart Failure Index, EQ-5D-5L, and the Kansas City Cardiomyopathy Questionnaire-12. Secondary outcome measures for this study include cost of health care services used and health outcomes. RESULTS: Patient recruitment began in November 2018 at the Sunnybrook Health Sciences Centre, with a total of 35 participants recruited by July 30, 2019 (17 in the intervention group and 18 in the control group). The final analysis is expected to occur in the fall of 2020. CONCLUSIONS: This RCT will be the first to assess the effectiveness of the Medly TM system for use following discharge from hospital after a HF-related decompensation. TRIAL REGISTRATION: ClinicalTrials.gov NCT03358303; https://clinicaltrials.gov/ct2/show/NCT03358303. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15753.
No takes yet. Share an insight, caveat, or question.
Seto et al. (2019) conducted a letter in Heart failure. Medly mobile phone-based telemonitoring program vs. Usual care was evaluated on Self-Care of Heart Failure Index (SCHFI). The Medly mobile phone-based telemonitoring program is the subject of a proposed randomized controlled trial protocol for heart failure patients, with no clinical results reported in this letter.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: